Zenas BioPharma financials
$26.76−2.87%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $10.0M | $5.0M |
| Gross profit | $10.0M | $5.0M |
| Gross margin | 100.0% | 100.0% |
| Operating income | -$383.1M | -$163.9M |
| Net income | -$377.7M | -$157.0M |
| Net margin | −3777.4% | −3139.8% |
| Diluted EPS | $-8.44 | $-11.89 |
| EBITDA | -$383.0M | -$163.8M |
| Operating cash flow | -$172.3M | -$119.7M |
| Free cash flow | -$172.4M | -$119.8M |
| Diluted shares | 44.7M | 13.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $110.6M | $319.7M |
| Short-term investments | $232.6M | $31.0M |
| Total debt | $0.00 | $0.00 |
| Total assets | $383.6M | $370.0M |
| Total liabilities | $141.5M | $57.5M |
| Shareholders' equity | $242.1M | $312.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology